4-Fluoroacetophenone

We are 4-Fluoroacetophenone CAS:403-42-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Fluoroacetophenone
CAS.NO:403-42-9
Synonyms:4-Fluoroacetophenone
Ethanone, 1-(4-fluorophenyl)-
1-(4-Fluorophenyl)ethanone
Molecular Formula:C8H7FO
Molecular Weight:138.13900
 
Physical and Chemical Properties:
Density:1.143
Melting point:4ºC
Boiling point:77-78ºC
Flash point:160°F
Index of Refraction:1.511
 
Specification:
Appearance:Colourless to yellow clear liquid
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Epoxiconazole.

4-Fluoroacetophenone


Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.132201-32-2 Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.3,4-Dimethoxyphenylboronic Acid CAS:122775-35-3 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.4-Amino-2,6-dichlorophenol CAS:5930-28-9 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
3-Methacryloxypropyltrimethoxysilane View Details
1,3-Dibromo-2,2-dimethoxypropane View Details
3-Chloro-2-cyanopyridine View Details
3-Chloropropyltrichlorosilane manufacturer DL-Glutamic acid monohydrate manufacturer 4-Aminopyrazolo[3,4-d]pyrimidine manufacturer 1-Fluoro-2,4-dinitrobenzene manufacturer 2-Bromobenzaldehyde manufacturer